TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia

Yang Li; Hanying Huang; Ziang Zhu; Shuzhao Chen; Yang Liang; Lingling Shu

doi:10.1016/j.isci.2023.107451

TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia

iScience. 2023 Jul 22;26(8):107451. doi: 10.1016/j.isci.2023.107451. eCollection 2023 Aug 18.

Authors

Yang Li^{1

2}, Hanying Huang^{1

2}, Ziang Zhu^{1

2}, Shuzhao Chen^{1

2}, Yang Liang^{1

2}, Lingling Shu^{1

2

3}

Affiliations

¹ State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
² Department of Hematological Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
³ State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong 999077, P.R. China.

Abstract

Acute myeloid leukemia (AML) is the type of hematologic neoplasm most common in adults. Glucocorticoid-induced gene TSC22D3 regulates cell proliferation through its function as a transcription factor. However, there is no consensus on the prognostic and immunoregulatory significance of TSC22D3 in AML. In the present study, we evaluated the correlation between TSC22D3 expression, immunoinfiltration, and prognostic significance in AML. Knockdown of TSC22D3 significantly attenuated the proliferation of Hel cells and increased sensitivity to cytarabine (Ara-c) drugs. Furthermore, TSC22D3 reduced the release of interleukin-1β (IL-1β) by inhibiting the NF-κB/NLRP3 signaling pathway, thereby inhibiting macrophage polarization to M1 subtype, and attenuating the pro-inflammatory tumor microenvironment. In conclusion, this study identified TSC22D3 as an immune-related prognostic biomarker for AML patients and suggested that therapeutic targeting of TSC22D3 may be a potential treatment option for AML through tumor immune escape.

Keywords: Cancer systems biology; Components of the immune system; Functional aspects of cell biology.